januvia: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995	NDA	Merck Sharp & Dohme LLC	0006-0112-28	100 BLISTER PACK in 1 CARTON (0006-0112-28) / 1 TABLET, FILM COATED in 1 BLISTER PACK (0006-0112-01)	2006-10-16
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995	NDA	Merck Sharp & Dohme LLC	0006-0112-31	30 TABLET, FILM COATED in 1 BOTTLE (0006-0112-31)	2006-10-16
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995	NDA	Merck Sharp & Dohme LLC	0006-0112-54	90 TABLET, FILM COATED in 1 BOTTLE (0006-0112-54)	2006-10-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

JANUVIA (sitagliptin) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for managing type 2 diabetes mellitus. As a dipeptidyl peptidase-4 (DPP-4) inhibitor, JANUVIA enhances glycemic control by prolonging the activity of incretin hormones. Given its global manufacturing and distribution, understanding the key suppliers involved in the production, formulation, and distribution of JANUVIA is essential for stakeholders in healthcare, investment, and supply chain management.

Manufacturers and Contract Manufacturers

The active pharmaceutical ingredient (API) for JANUVIA, sitagliptin, is primarily produced by Januvia's originator company, Merck & Co. (MSD outside the U.S. and Canada). Merck has established a robust supply chain that includes multiple API producers, formulation facilities, and global distribution partners.

Active Pharmaceutical Ingredient (API) Suppliers

Merck & Co. (MSD):
As the originator, Merck manufactures sitagliptin API primarily through internal facilities and contracted API production. The company has strategically partnered with several manufacturing entities globally to ensure scale, quality, and supply continuity.
Contract Manufacturing Organizations (CMOs):
Several contract manufacturing firms serve as API suppliers for Merck, including:
- Par Pharmaceuticals (a division of Endo Pharmaceuticals): Historically involved in formulation and possibly API intermediates.
- Strides Shasun (India): Recognized for active pharmaceutical ingredients manufacturing.
- Hetero Labs (India): Known for bulk pharmaceutical chemicals, including APIs for diabetes medications.
These partnerships allow Merck to diversify sources and mitigate supply chain disruptions.

Formulation and Finished Product Manufacturing

Merck's Own Manufacturing Facilities:
Merck operates manufacturing plants globally, including facilities in the U.S., Puerto Rico, and Europe, for the formulation and packaging of JANUVIA tablets.
Third-party Contract Manufacturers:
Merck licenses or partners with third-party OEMs in various regions to expand production capacity to meet global demand.

Distribution and Supply Chain Partners

Post-manufacture, JANUVIA is distributed through a network of authorized wholesalers, specialty pharmacies, and distribution channels worldwide.

Merck's Global Distribution Network:
Merck maintains a sophisticated supply chain infrastructure, including direct partnerships with major pharmaceutical distributors such as McKesson, Cardinal Health, and Owens & Minor.
Regional Distributors:
In emerging markets, local distributors and importers facilitate access to JANUVIA, often sourcing directly from Merck or regional manufacturing partners.
Pharmacy Benefit Managers (PBMs):
PBMs play a critical role in formulary placement, influencing supply flow within insurance networks.

Supply Chain Risks and Diversification Strategies

The reliance on multiple API suppliers and regional manufacturing partnerships reduces dependency on a single source, but global supply chains remain vulnerable to geopolitical, logistical, or regulatory disruptions. Merck's strategic alliances, supply chain monitoring, and contingency planning are critical components ensuring consistent JANUVIA availability.

Competitive and Market Dynamics

While the original supply chain is predominantly Merck-led, biosimilar and generic manufacturers have entered the market, sourcing API from various global suppliers. Competitors include:

Teva Pharmaceuticals:
Offers sitagliptin generics, sourcing API from Indian manufacturers like Hetero Labs.
Zydus Cadila:
Produces generic sitagliptin, with supply chains involving Indian API producers.
Biocon and Other Indian Manufacturers:
Engage in API production for biosimilar variants and generics, often sourcing from the same regional API suppliers.

Regulatory and Quality Considerations

Suppliers of sitagliptin API and formulated JANUVIA must comply with stringent regulatory standards such as the FDA's Current Good Manufacturing Practice (cGMP) guidelines. Merck's proactive oversight and collaboration with international regulatory agencies help maintain product quality and consistency.

Future Outlook & Industry Trends

Diversification of API Suppliers:
To mitigate risks, Merck and other key players are continuously expanding and qualifying additional API manufacturing sites, especially in India and China.
Advancements in Manufacturing Technology:
Innovations such as continuous manufacturing may improve efficiency, quality control, and supply flexibility.
Patent and Market Dynamics:
The expiration of key patents may lead to increased competition, with generic manufacturers sourcing APIs from established suppliers to produce cost-effective alternatives.

Key Takeaways

Merck & Co. remains the primary driver behind JANUVIA’s supply chain, controlling API production and formulation globally.
Indian pharmaceutical manufacturers, including Hetero Labs and Strides Shasun, are significant API suppliers, providing cost-effective sources for the generic market.
Third-party CMOs and regional distributors play critical roles in expanding capacity and regional availability across North America, Europe, and emerging markets.
Supply chain risks are mitigated through diversification of suppliers and regional manufacturing hubs, but geopolitical and logistical factors continue to influence stability.
Regulatory compliance and quality assurance are central to maintaining trust and continuous supply, particularly amid increasing global regulatory scrutiny.

FAQs

1. Who are the main API suppliers for JANUVIA?
Most API production for sitagliptin is managed by Merck, supplemented by Indian API manufacturers such as Hetero Labs and Strides Shasun, which serve both Merck and generic manufacturers.

2. Are there alternative suppliers for JANUVIA’s active ingredient?
Yes. Generic producers sourcing from Indian API manufacturers like Hetero Labs and Zydus Cadila have entered the market as patent protections for JANUVIA expire.

3. How does Merck ensure the quality of its sitagliptin supply chain?
Merck maintains strict quality controls, conducts regular audits, and requires regulatory compliance (e.g., cGMP) from all manufacturing partners to ensure high standards.

4. What risks are associated with the supply chain of JANUVIA?
Risks include geopolitical instability, manufacturing disruptions, regulatory changes, and raw material shortages, especially in regions with concentrated API production.

5. Will the supply chain for JANUVIA change with emerging biosimilars and generics?
Yes. As patents expire, more generic manufacturers will produce sitagliptin, often sourcing APIs from the same major suppliers, increasing competition and diversifying the supply chain.

References

FDA. (2023). Prescribing Information for JANUVIA® (sitagliptin).
Merck & Co. Official Website. (2023). Manufacturing and Supply Chain Details.
Indian Pharmaceutical Industry Reports. (2022). API Manufacturing and Global Market Share.
Pharmaceutical Technology. (2021). Contract Manufacturing and API Supply Chain Strategies in the Diabetes Sector.
World Health Organization. (2022). Good Manufacturing Practices (GMP) Guidelines.

This report provides key insights into JANUVIA's global supply ecosystem, supporting informed decision-making for industry stakeholders.

Suppliers and packagers for januvia

januvia

Suppliers for the Pharmaceutical Drug: JANUVIA (Sitagliptin)